Among TAVI patients who have an indication for anticoagulation, direct oral anticoagulants (DOACs) appear to provide better outcomes than do vitamin K antagonists (VKAs), according to a French ...

Doctor giving emotional support to a senior patient using face mask In a landmark trial presented at AHA 2021, researchers aimed to understand the safety and efficacy of direct oral anticoagulants vs ...

Results from the FRAIL-AF study, being presented at the European Society of Cardiology 2023 Congress, surprised the investigators. In a study that will likely turn heads among cardiologists, findings ...

NEW YORK, NY—Patients undergoing TAVI who have an indication for oral anticoagulation are less likely to die over 5 years of follow-up if they’re discharged on a direct oral anticoagulant (DOAC) ...

Contrary to expectations, vitamin K antagonists (VKAs) reduced the risk for ischemic stroke and death compared with the factor Xa inhibitor rivaroxaban (Xarelto, Janssen) in patients with rheumatic ...

A recent study published in JAMA found an association between treatment with dicloxacillin and a decrease in international normalized ratio (INR) levels among patients taking vitamin K antagonists ...

Janssen has announced results from its Phase 3b exploratory trial evaluating the efficacy of Xarelto (rivaroxaban) as an alternative to vitamin K antagonists (VKAs) for treating and reducing the risk ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Vitamin K antagonists have been extensively used as the ...

Prognostic factors of survival after radiotherapy for metastases to the spinal column and a scoring system of survival: Review of 530 patients in Shizuoka Cancer Center Hospital CLOT N=676 Dalteparin ...

Close-up of home caregiver and senior woman holding hands The authors observed that AF patients taking DOACs are less likely to experience dementia or cognitive decline than those prescribed vitamin K ...